Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2CNS 1

Conditions

Sarcoma 1Oligodendroglioma 1Gliosarcoma 1Glioma 1Glioblastoma 1Astrocytoma 1

Interventions

pembrolizumab 1254Specimen Handling 869Carboplatin 818Magnetic Resonance Spectroscopy 804Cyclophosphamide 795Cisplatin 716Nivolumab 648Paclitaxel 623Radiotherapy 567Gemcitabine 565Biopsy 529Bevacizumab 468Dexamethasone 434fludarabine 404Docetaxel 373venetoclax 366Oxaliplatin 362Capecitabine 353Fluorouracil 352atezolizumab 341Rituximab 327durvalumab 326Doxorubicin 313Radiosurgery 306Pemetrexed 303Drug Therapy 295Standard of Care 292Ipilimumab 290Etoposide 280Radiation 278

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × abexinostat × 1 year × Clear all
NCT05698524 2026-04-17

A Study of Temodar With Abexinostat (PCI-24781) for Patients With Recurrent Glioma

University of Nebraska

Phase 1 Recruiting
24 enrolled
CNSSarcoma

Astrocytoma, Glioblastoma, Glioma, Oligodendroglioma, Gliosarcoma

NCT01027910 2025-07-24

PCI-24781 in Combination With Doxorubicin to Treat Sarcoma

Massachusetts General Hospital

Phase 1/2 Completed
20 enrolled 10 charts
Sarcoma

Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡